FDA lifts partial hold on imetelstat study; Geron leaps
This article was originally published in Scrip
Executive Summary
Shares of Geron rocketed 33.5% on 12 June after the company said the FDA lifted a partial hold on an investigator-led study of the firm's experimental telomerase inhibitor imetelstat (GRN163L).